Opinion
Late-cycle opportunities in new cancer treatment
Stirling LarkinColumnistWhatever one’s view of where we are in the collective global cycle, pretty much everyone can agree that 2019 is long in the tooth and can safely be dubbed "late cycle".
Late cycles display some very particular attributes. Traditionally there is a flurry of merger and acquisition "megadeals" within incumbent industries, as well as a barrage of new upstarts, reflected in initial public offering (IPOs).
Loading...
Stirling Larkin writes on global investing and ultra high net worth wealth. He is chief investment officer of investment manager Australian Standfirst.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Personal finance
Fetching latest articles